Clinical Trial Update: Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anlotinib hydrochloride capsules combined with CAPEOX in RAS and BRAF wild-type metastatic colorectal cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anlotinib hydrochloride capsules (anlotinib hydrochloride)
• CAPEOX

Snippet

Sponsor: Zhejiang University | Conditions: Colorectal Cancer, RAS and BRAF Wild-type | Phase 2 | Status: COMPLETED